NLRP3-IN-9
NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2768759-64-2
- Formel: C16H19N2NaO5S
- Molecular Weight:374.39
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
NLRP3 |
In Vitro
NLRP3-IN-9 (compound 4b) (0.01-3 µM) inhibits IL-1β release in a dose-dependent manner in ATP (5 mM) and LPS (1 µg/mL)-induced macrophages[1].
NLRP3-IN-9 (1 µM; 15 min) inhibits NLRP3 inflammasome oligomerization[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Macrophages
-
Concentration:1 µM
-
Incubation Time:15 min
-
Result:Inhibited teh expression of IL-1β P17, Casp-1 p10 peotein levelwith the ATP (5 mM) and LPS (1 µg/mL)-induced in the supernatant of the cultures, without affecting the intracellular levels of their precursors.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:3-4 month old male and female C57BL/6J WT and NLRP3-KO mice[1]
-
Dosage:3, 10 mg/kg
-
Administration:I.p.
-
Result:Reduced paw swelling by 40% in males and 33% in females at 3 mg/kg, and 66% in males and 52% in females at 10 mg/kg in WT mouse.
Chemical Information
-
CAS. Nr. 2768759-64-2
-
Molecular Weight 374.39
-
Formel C16H19N2NaO5S
-
SMILES
O=C(N([Na])S(C1=CC(C(C)(O)C)=CO1)(=O)=O)NC2=CC(C)=CC(C)=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)